A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Superiority of CRx-102 [dipyridamole/prednisolone] Over Each of Its Components When Given to Subjects With Active Rheumatoid Arthritis (RA).

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Superiority of CRx-102 [dipyridamole/prednisolone] Over Each of Its Components When Given to Subjects With Active Rheumatoid Arthritis (RA).

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2014

At a glance

  • Drugs Dipyridamole/prednisolone (Primary) ; Dipyridamole; Prednisolone
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MARS-1
  • Sponsors Zalicus
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jun 2012 Additional trial location (United Kingdom) identified as reported by EudraCT (Extension trial: EudraCT2007-004399-38).
    • 30 Jun 2012 Additional trial location (United Kingdom) identified as reported by EudraCT (Extension trial: EudraCT2007-004399-38).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top